ELEV - Elevation Oncology: Mid-2024 EO-3021 Data Could Get Ball Rolling

2024-05-03 13:16:04 ET

Summary

• Results from the phase 1 study, using EO-3021 for the treatment of CLDN 18.2 expressing solid tumors, expected mid-Q3 of 2024; Additional data expected 1st half of 2025.
• HER3-ADC is another ADC being developed in the pipeline for the treatment of patients with HER3-expressning solid tumors; It has been shown that up to 42% of tumors express HER3.
• Nomination of ADC candidate for HER3-ADC clinical program expected in the 2nd half of 2024.
• Plans, to advance EO-3021 in combination with another cancer drug to treat patients with advanced solid tumors, expected in the 1st half of 2024.

Elevation Oncology, Inc. ( ELEV ) is gearing up to report data from its phase 1 study to treat patients with advanced solid tumors, using its drug EO-3021, in mid-Q3 of 2024. This will be a major inflection point for investors to keep an eye on because it will be possible that it could establish proof-of-concept in being able to treat these patients. Specifically, it is targeting advanced solid tumor types such as: Gastric, gastroesophageal junction, pancreatic or esophageal cancers....

For further details see: